AR007160A1 - Compuestos antagonistas del receptor de adhesion, procedimiento para preparar estos compuestos y preparaciones farmaceuticas que los contienen - Google Patents
Compuestos antagonistas del receptor de adhesion, procedimiento para preparar estos compuestos y preparaciones farmaceuticas que los contienenInfo
- Publication number
- AR007160A1 AR007160A1 ARP970102054A ARP970102054A AR007160A1 AR 007160 A1 AR007160 A1 AR 007160A1 AR P970102054 A ARP970102054 A AR P970102054A AR P970102054 A ARP970102054 A AR P970102054A AR 007160 A1 AR007160 A1 AR 007160A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- preparing
- pharmaceutical preparations
- receptor antagonist
- preparations containing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000019997 adhesion receptor Human genes 0.000 title abstract 2
- 108010013985 adhesion receptor Proteins 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000000010 osteolytic effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a los compuestos antagonistas del receptor de adhesión de fórmula (I), en la que R1, R2, R2, R3, U, V, W, X, Y, Ar, m, n, n, p y qtienen los significados indicados en la reivindicación 1, y a sus sales. También se refiere au n procedimiento para preparar estos compuestos, apreparaciones farmacéuticas que los contienen y al empleo de los mismos para preparar un medicamento. Los compuestos inhiben la unión de fibrinógeno alreceptor correspondiente, y se adecuan paracom batir las trombosis, osteoporosis, enfermedades tumorales, la apoplejía, el infarto de miocardio,las isquemias, las inflamaciones, la arterioesclerosis y las enfermedades osteolíticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19620041A DE19620041A1 (de) | 1996-05-17 | 1996-05-17 | Adhäsionsrezeptor-Antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007160A1 true AR007160A1 (es) | 1999-10-13 |
Family
ID=7794651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970102054A AR007160A1 (es) | 1996-05-17 | 1997-05-16 | Compuestos antagonistas del receptor de adhesion, procedimiento para preparar estos compuestos y preparaciones farmaceuticas que los contienen |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR007160A1 (es) |
| AU (1) | AU2957997A (es) |
| DE (1) | DE19620041A1 (es) |
| WO (1) | WO1997044333A1 (es) |
| ZA (1) | ZA974234B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU729488B2 (en) * | 1996-08-29 | 2001-02-01 | Merck & Co., Inc. | Compositions and methods for administering integrin receptor antagonists |
| PL341984A1 (en) | 1998-01-28 | 2001-05-07 | Shionogi & Co | Novel tricycle compounds |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| EP1054871A2 (en) * | 1998-04-01 | 2000-11-29 | Du Pont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US6107313A (en) * | 1998-10-02 | 2000-08-22 | Combichem, Inc. | Dopamine receptor antagonists |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| JP2003531141A (ja) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | エナミン誘導体 |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
| WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
| JP2004505110A (ja) | 2000-08-02 | 2004-02-19 | セルテック アール アンド ディ リミテッド | 3位置換イソキノリン−1−イル誘導体 |
| US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| AU2002313633B2 (en) * | 2001-06-08 | 2007-03-01 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
| AU2003276043A1 (en) | 2002-06-17 | 2003-12-31 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| JP2006516144A (ja) | 2002-12-20 | 2006-06-22 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物 |
| US20050043344A1 (en) * | 2002-12-20 | 2005-02-24 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists derivatives |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| ES2887054T3 (es) * | 2003-04-11 | 2021-12-21 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| WO2006044456A1 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| EP1893591A1 (en) * | 2005-06-08 | 2008-03-05 | Novartis AG | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| EP1907383A1 (en) * | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
| IN2014CN04406A (es) | 2006-03-30 | 2015-09-04 | Ptc Therapeutics Inc | |
| PT3357911T (pt) | 2006-06-26 | 2022-07-11 | Akebia Therapeutics Inc | Inibidores da prolil-hidroxilase e métodos de utilização |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| US8362050B2 (en) * | 2008-06-24 | 2013-01-29 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
| NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
| WO2012170442A1 (en) | 2011-06-06 | 2012-12-13 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| EP3007695B1 (en) | 2013-06-13 | 2024-02-07 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| CR20160222U (es) | 2013-11-15 | 2016-08-26 | Akebia Therapeutics Inc | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas |
| WO2015134711A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| CA2974691A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| CN108348527A (zh) | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| JP7440989B2 (ja) | 2018-05-09 | 2024-02-29 | アケビア セラピューティクス インコーポレイテッド | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| GB202209228D0 (en) * | 2022-06-23 | 2022-08-10 | Univ Strathclyde | Modified amino acids and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB935523A (en) * | 1961-06-17 | 1963-08-28 | Acraf | New sulphamido-oxadiazoles |
| JPS51143669A (en) * | 1975-06-06 | 1976-12-10 | Takeda Chem Ind Ltd | A process for preparing 1,2,4- oxadiazole derivatives |
| JPS52272A (en) * | 1975-10-17 | 1977-01-05 | Takeda Chem Ind Ltd | Process for preparing 1,2,4-oxadiazole derivatives |
| US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| WO1994022846A1 (en) * | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
-
1996
- 1996-05-17 DE DE19620041A patent/DE19620041A1/de not_active Withdrawn
-
1997
- 1997-05-15 ZA ZA9704234A patent/ZA974234B/xx unknown
- 1997-05-16 AR ARP970102054A patent/AR007160A1/es unknown
- 1997-05-20 AU AU29579/97A patent/AU2957997A/en not_active Abandoned
- 1997-05-20 WO PCT/EP1997/002555 patent/WO1997044333A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997044333A1 (de) | 1997-11-27 |
| DE19620041A1 (de) | 1998-01-29 |
| ZA974234B (en) | 1997-12-11 |
| AU2957997A (en) | 1997-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR007160A1 (es) | Compuestos antagonistas del receptor de adhesion, procedimiento para preparar estos compuestos y preparaciones farmaceuticas que los contienen | |
| MX9504630A (es) | Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| AR003121A1 (es) | Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades | |
| LU91145I2 (fr) | FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX). | |
| AR062931A2 (es) | Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos | |
| MX9706069A (es) | Nuevos inhibidores de la trombina. | |
| CO4930259A1 (es) | Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen | |
| AR001332A1 (es) | Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen. | |
| AR006273A1 (es) | Compuestos heterociclicos nitrogenados de anillos de 5 miembros como nuevos inhibidores de la resorcion osea y antagonistas de receptores de vitronectina,procedimiento para su preparacion, utilizacion de dichos compuestos para la preparacion de un medicamento, y preparado farmaceutico. | |
| NO301419B1 (no) | 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler | |
| ES2060951T3 (es) | Azaindenos. | |
| HN1998000157A (es) | Agonistas de prostaglandinas | |
| ES2110761T3 (es) | Pirrolidin-3-il-alquil-piperidinas sustituidas utiles como antagonistas de la taquiquinina. | |
| ES2183332T3 (es) | Aminoacidos biciclicos aromaticos. | |
| CO4650038A1 (es) | Derivados del indazol sustituidos y compuestos relacionados | |
| MX9305947A (es) | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR002245A1 (es) | Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos. | |
| TR199701645A2 (xx) | Vitronektin resept�r antagonistleri,bunlar�n imalat� ve kullan�m� | |
| ES2192621T3 (es) | Sales de derivados de quinoleina como antagonistas de nk3. | |
| MX9304424A (es) | Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
| UY26988A1 (es) | Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos. | |
| EP0888345A4 (en) | SIGMA-2 RECEPTORS AS A BIOMARKER OF TUMOR CELL PROLIFERATION | |
| MX9300306A (es) | Bencimidazoles medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
| ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. |